Abstract
Premature ejaculation is one of the most prevalent sexual disorders affecting men today. The lack of approved therapies has resulted in the prescription of many ‘off-label’ treatments to manage the condition. Selective serotonin reuptake inhibitors have an interesting side effect of prolonging ejaculatory latency. Consequently, these agents are often considered a first line treatment for patients suffering from premature ejaculation. Erectile dysfunction is another common side effect reported by men treated with selective serotonin reuptake inhibitors. Nitric oxide is the primary mediator of erectile function. Preclinical studies have provided evidence that selective serotonin reuptake inhibitors decrease nitric oxide bioavailability. This invited mini-review aims to examine the physiology of the erectile and ejaculatory responses, discuss the indicated and ‘off-label’ clinical utility of selective serotonin reuptake inhibitors, and to summarize evidence from basic science and clinical studies pertaining to mechanisms of how selective serotonin reuptake inhibitor therapy modifies ejaculatory and erectile function.
Keywords: Erectile dysfunction, PE treatment, premature ejaculation, selective serotonin reuptake inhibitor, SSRI.
Current Drug Safety
Title:Selective Serotonin Reuptake Inhibitors for Premature Ejaculation: Review of Erectile and Ejaculatory Side Effects
Volume: 9 Issue: 2
Author(s): George F. Lasker, Fikret Halis and Ahmet Gokce
Affiliation:
Keywords: Erectile dysfunction, PE treatment, premature ejaculation, selective serotonin reuptake inhibitor, SSRI.
Abstract: Premature ejaculation is one of the most prevalent sexual disorders affecting men today. The lack of approved therapies has resulted in the prescription of many ‘off-label’ treatments to manage the condition. Selective serotonin reuptake inhibitors have an interesting side effect of prolonging ejaculatory latency. Consequently, these agents are often considered a first line treatment for patients suffering from premature ejaculation. Erectile dysfunction is another common side effect reported by men treated with selective serotonin reuptake inhibitors. Nitric oxide is the primary mediator of erectile function. Preclinical studies have provided evidence that selective serotonin reuptake inhibitors decrease nitric oxide bioavailability. This invited mini-review aims to examine the physiology of the erectile and ejaculatory responses, discuss the indicated and ‘off-label’ clinical utility of selective serotonin reuptake inhibitors, and to summarize evidence from basic science and clinical studies pertaining to mechanisms of how selective serotonin reuptake inhibitor therapy modifies ejaculatory and erectile function.
Export Options
About this article
Cite this article as:
Lasker F. George, Halis Fikret and Gokce Ahmet, Selective Serotonin Reuptake Inhibitors for Premature Ejaculation: Review of Erectile and Ejaculatory Side Effects, Current Drug Safety 2014; 9 (2) . https://dx.doi.org/10.2174/1574886309666140120095846
DOI https://dx.doi.org/10.2174/1574886309666140120095846 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treating Dyslipidemias: Is Inflammation the Missing Link?
Medicinal Chemistry Dietary Fish Oil Reduces Colon Cancer Risk
Current Organic Chemistry Lyn Regulates Cytotoxicity in Respiratory Epithelial Cells Challenged by Cigarette Smoke Extracts
Current Molecular Medicine Current Applications of Artificial Neural Networks in Biochemistry with Emphasis on Cancer Research
Current Biochemical Engineering (Discontinued) The Management of the Infected Diabetic Foot
Current Diabetes Reviews Human Clinical Studies of Tea Polyphenols in Allergy or Life Style-related Diseases
Current Pharmaceutical Design Beclin 1 Biology and its Role in Heart Disease
Current Cardiology Reviews Role of Polyphenols in Diet and Nutrition-An Updated Review
Current Nutrition & Food Science Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine The Role of Calcium and the L-Type Calcium Channel in Pathological Remodeling of the Heart
Vascular Disease Prevention (Discontinued) The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Blood Pressure and Vascular Alterations with Growth in Childhood
Current Pharmaceutical Design Editorial: Inflammation and Heart Diseases
Current Pharmaceutical Design Evaluation of Therapeutic Agents Targeting the Pathogenesis of Coronary Artery Spasm: A Mini Review
Current Vascular Pharmacology Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials
Current Clinical Pharmacology Long-term Outcomes of Mitral Valve Repair Versus Replacement for Degenerative Disease: A Systematic Review
Current Cardiology Reviews Pro-Angiogenic Effect of Endomyocardial Biopsy-Derived Cells for Cardiac Regeneration
Current Tissue Engineering (Discontinued) Type 2 Diabetes and Risk for Functional Decline and Disability in Older Persons
Current Diabetes Reviews Prevalence and Associated Risk Factors of Hyperglycemia and Diabetes Mellitus Among HIV Positive Patients in Tehran, Iran
Infectious Disorders - Drug Targets Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets